Inhibrx (NASDAQ:INBX – Get Free Report) released its quarterly earnings data on Monday. The company reported ($3.09) earnings per share for the quarter, missing the consensus estimate of ($2.88) by ($0.21), Zacks reports. The firm had revenue of $0.10 million during the quarter.
Inhibrx Stock Down 1.1 %
NASDAQ:INBX opened at $13.94 on Tuesday. The stock’s fifty day moving average price is $13.33 and its two-hundred day moving average price is $14.67. Inhibrx has a 52-week low of $10.80 and a 52-week high of $35.42.
Wall Street Analyst Weigh In
Separately, JMP Securities restated a “market perform” rating on shares of Inhibrx in a research report on Wednesday, January 22nd.
About Inhibrx
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Featured Stories
- Five stocks we like better than Inhibrx
- Canada Bond Market Holiday: How to Invest and Trade
- Is Intuitive Machines a Buy After Athena’s Disappointing Landing?
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Joby Aviation Stock: Virgin Atlantic Deal Signals Big Potential
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Kohl’s Posts Another Kitchen Sink Quarter, But New CEO Has a Plan
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.
